Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2022 Sep 29;20(1):320.
doi: 10.1186/s12957-022-02783-z.

Prognostic role of the systemic immune-inflammation index in biliary tract cancers: a meta-analysis of 3,515 patients

Buwen Zhang  1 , Weiyun Yao  2
Affiliations
Meta-Analysis

Prognostic role of the systemic immune-inflammation index in biliary tract cancers: a meta-analysis of 3,515 patients

Buwen Zhang et al. World J Surg Oncol. .

Abstract

Background: The systemic immune-inflammation index (SII) is an inflammatory parameter calculated as platelet count × neutrophil count/lymphocyte count in the peripheral blood. In recent years, the prognostic role of the SII in patients with biliary tract cancer (BTC) has been gradually investigated. However, the results were controversial. This meta-analysis aimed to illustrate the prognostic value of the SII in BTC.

Methods: The electronic databases of PubMed, the Web of Science, Embase, and the Cochrane Library were thoroughly retrieved up to April 15, 2022. Pooled hazard ratios (HRs) with 95% confidence intervals (CIs) were used to evaluate the prognostic value of the SII for clinical outcomes. The association between the SII and overall survival (OS) and recurrence-free survival (RFS)/progression-free survival (PFS) was evaluated.

Results: Thirteen studies involving 3515 patients were included in this meta-analysis. The pooled results indicated that an elevated SII was significantly associated with poor OS (HR, 1.77; 95% CI, 1.47-2.14; p<0.001) and RFS/PFS (HR, 1.66; 95% CI, 1.38-1.99; p<0.001) in patients with BTC. Subgroup analysis stratified by country, sample size, and cutoff value showed similar results. The sensitivity analysis and publication bias test confirmed the reliability of our results.

Conclusions: An elevated pretreatment SII was significantly associated with worse OS and RFS/PFS in patients with BTC. Our results suggest that the SII is a valuable and cost-effective prognostic parameter for the treatment of patients with BTC.

Keywords: Biliary tract cancers; Meta-analysis; Prognosis; Risk factors; Systemic immune-inflammation index.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Flow diagram of the literature search and selection
Fig. 2
Fig. 2
Forest plot for the relationship SII and OS in BTC patients
Fig. 3
Fig. 3
Forest plot for the relationship SII and RFS/PFS in BTC patients
Fig. 4
Fig. 4
Result of sensitivity analyses by omitting one study in each turn for (A) OS and (B) RFS/PFS
Fig. 5
Fig. 5
Publication bias test by Begg’s funnel plot and Egger’s test. A Begg’ test for OS, p=0.079; B Egger’s test for OS, p= 0.088; C Begg’ test for RFS/PFS, p=0.260; D Egger’s test for RFS/PFS, p= 0.193
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Valle JW, Kelley RK, Nervi B, Oh DY, Zhu AX. Biliary tract cancer. Lancet. 2021;397(10272):428–444. doi: 10.1016/S0140-6736(21)00153-7. - DOI - PubMed
    1. Kone LB, Bystrom PV, Maker AV. Robotic surgery for biliary tract cancer. Cancers (Basel). 2022;14(4):1046. - PMC - PubMed
    1. Pezzicoli G, Triggiano G, Sergi MC, Mannavola F, Porta C, Tucci M. Biliary tract cancers: moving from the present standards of care towards the use of immune checkpoint inhibitors. Am J Transl Res. 2021;13(8):8598–8610. - PMC - PubMed
    1. Sasaki T, Takeda T, Okamoto T, Ozaka M, Sasahira N. Chemotherapy for biliary tract cancer in 2021. J Clin Med. 2021;10(14):3108. - PMC - PubMed
    1. Mukkamalla SKR, Naseri HM, Kim BM, Katz SC, Armenio VA. Trends in incidence and factors affecting survival of patients with cholangiocarcinoma in the United States. J Natl Compr Cancer Netw. 2018;16(4):370–376. doi: 10.6004/jnccn.2017.7056. - DOI - PubMed

Publication types

LinkOut - more resources